# Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

> **NCT06401642** · PHASE4 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 200 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Zavegepant

## Key facts

- **NCT ID:** NCT06401642
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-22
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401642, "Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06401642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*